S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

OncLive® On Air - En podkast av OncLive® On Air

Prøv Podimo gratis i hele 60! dager!

Prøv Podimo gratis i hele 60! dager!

I Podimo finner du eksklusive podkaster og bestselgende lydbøker tilpasset dine ører

 Reklame
Podcast artwork

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

Visit the podcast's native language site